Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nat Med. 2004 Sep;10(9):909-15.

    Cancer immunotherapy: moving beyond current vaccines.

    Source

    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA. sar@mail.nih.gov

    Abstract

    Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

    Comment in

    PMID:
    15340416
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1435696
    Free PMC Article

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk